Pure Red Cell Aplasia Research Study
|
Daclizumab for Pure Red Cell Aplasia
|
If you or someone you know has been diagnosed with Pure Red Cell Aplasia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether daclizumab, a genetically engineered human monoclonal antibody, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
To find out if you qualify , please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
Protocol Information |
|
|
Disease and Treatment Information |
|
|
Support Groups |
|
|
|
|
Pure Red Cell Aplasia Research Study
|
Rituximab (Rituxan) for Pure Red Cell Aplasia
|
If you have been diagnosed with Pure Red Cell Aplasia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether rituximab (Rituxan), a genetically engineered monoclonal antibody therapy, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If you are determined eligible to participate, you will be treated with an infusion of rituximab once every week for a total of 4 doses and then followed to evaluate for response
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
Protocol Information |
|
|
Disease and Treatment Information |
|
|
Support Groups |
|
|
|
|
Pure Red Cell Aplasia Research Study
|
Stem Cell Transplant for Patients with Pure Red Cell Aplasia
|
If you have been diagnosed with pure red cell aplasia, you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home. To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
Protocol Information |
|
|
Disease and Treatment Information |
|
|
Support Groups |
|
|
|
|
|